tients were treated with 1505 CS (mean age, 71 ± 9 years, range 43-92; male, 59%). The neuroradiological pre-procedural evaluation was performed with CT scan and / or MRI, Doppler, DSA, parenquimography before and after the procedure, and actually we perform perfusion study with Flat Panel. Brain protection device used at the beginning was the Theron original device, and then commercially available devices, including distal occlusion, filters and flow reversal. Clinical and neurological f-up was performed by independent neuro and cardiologist with NIH scale and Modified Ranking Scale (mRS), and monitoring by carotid Doppler and angiography was done in selected cases. Results: 77.8% of the patients were symptomatic and average CS was of 80%. Technical success was obtained in 96.4%, with a residual stenosis in less than 30%. According to mRS, value obtained was less than 2 points in 94.8% of patients. The periprocedural mortality rate at 30 days was 0.3%, neurological complications 2.8%. The combined risk ratio for stroke, myocardial infarction or death was 3.3%. Follow up was accomplished in 93.9% of patients, including assessment by carotid Doppler at day 30, 90 and 180 post-procedure. At 1 year follow-up, the combined risk ratio for Stroke, myocardial infarction or death was 5.9%. Conclusions: In our experience, CAS is a safe and effective procedure when performed in specialized centers and can achieve comparable Results: to endarterectomy.